Abstract
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rolf Rau, Oliver Sander, Piet van Riel, Leo van de Putte, Fritz Hasler, Michel Zaug, Johannes Kneer, Philippe van der Auwera, Randall M Stevens and Rheumatology Group 791
The Journal of Rheumatology April 2003, 30 (4) 680-690;
Rolf Rau
Oliver Sander
Piet van Riel
Leo van de Putte
Fritz Hasler
Michel Zaug
Johannes Kneer
Philippe van der Auwera
In this issue
The Journal of Rheumatology
Vol. 30, Issue 4
1 Apr 2003
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rolf Rau, Oliver Sander, Piet van Riel, Leo van de Putte, Fritz Hasler, Michel Zaug, Johannes Kneer, Philippe van der Auwera, Randall M Stevens, Rheumatology Group 791
The Journal of Rheumatology Apr 2003, 30 (4) 680-690;
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rolf Rau, Oliver Sander, Piet van Riel, Leo van de Putte, Fritz Hasler, Michel Zaug, Johannes Kneer, Philippe van der Auwera, Randall M Stevens, Rheumatology Group 791
The Journal of Rheumatology Apr 2003, 30 (4) 680-690;